Rayos noma iPrednisone - Okudingeka Ukwazi

I-Corticosteroid Yenzelwe Ukukhululwa Kancane

U-Rayos ( prednisone ), owaziwa ngokuthi iLototra eYurophu, ukwakhiwa kokubambezeleka kokukhululwa kwe-dozen prednisone ephansi. U-Rayos, okwakhiwa i-Horizon Pharma, wamukelwa yi-US Food and Drug Administration (FDA) ngoJulayi 26, 2012, ngenxa ye- arthritis ye- rheumatoid nezinye izinkomba eziningana.

Imvume ye-FDA isekelwe emininingwaneni eyaqhathaniswa ne-pharmacokinetics (ie, ukuthi imithi idonsa kanjani, isetshenziswe, isuswe) kaRayos ekudaleni ngokushesha i-prednisone, kanye nedatha evela ku-Circadian Administration of Prednisone ku-RA (CAPRA-1 no-2 ) ukulingwa.

I-CAPRA-2 yembula ukuthi abantu abane-arthritis enesisindo esiyinkimbinkimbi ababenesifo sikaRayos babhekene nokuthuthukiswa okuphawulekayo kwe- ACR20 ye-respondence criteria uma kuqhathaniswa ne-placebo, kanye nokuthuthukiswa okuphawulekayo ezingeni lokukhathala. I-CAPRA-1 ihlolwe ukuphepha jikelele kukaRayos.

Izinkomba

I-Rayos iyi- corticosteroid ene-anti-inflammatory or immunosuppressive effect esetshenziselwa ukwelapha isifo esithile, i-dermatologic, i-endocrine, isisu, i-hematologic, i-neoplastic, isimiso sezinzwa, i-ophthalmologic, i-renal, i-respiratory, ne-rheumatologic.

Ngokuphathelene nezimo ze-rheumatologic, uRayos angase asetshenziselwe ukuphumula okwesikhashana kwesigamu esiphuthumayo se-arthritis gouty. I-Rayos ingasetshenziswa futhi kwezinye izimo ze- ankylosing spondylitis , i-dermatomyositis, i-polymyositis, i- polymyalgia rheumatica , i- psoriatic arthritis , ibuyele i-polychondritis, i-rheumatoid arthritis, i- Sjogren's syndrome , i- systemic lupus erythematosus , ne- vasculitis .

Ukutholakala

I-Rayos iyatholakala njengo-1 mg., 2 mg., No-5 mg. ithebhulethi yokulinda ukulibala.

Ukuzikhohlisa

Ukuzikhethela kufanele kube ngabanye ngokucatshangelwa okunikezwe ubuhlungu besifo nokuthi ngabe iziguli zisebenzisa i-prednisone ngokushesha. Isibalo sokuqala sivame ukuba ngu-5 mg. kaRayos kanye ngosuku. Kodwa-ke, iziguli okwamanje ezidalwa i-prednisone zingadinga ukulungiswa kwesilinganiso ukuze zenze okulinganayo uma zishintsha ku-Rayos.

U-Rayos kufanele athathwe ngokudla, futhi ithebulethi kumele ithathwe. Ukuze isondlo, umthamo ophansi kunazo zonke kufanele usetshenziswe. Ukuqeda kufanele kube kancane kancane.

Ukusabela okubi

Ukusabela okubi okuvame kakhulu okuhlobene nokusetshenziswa kwe-corticosteroid kufaka ukugcinwa komthamo, ukuphakama kwegazi, ukuguquka kokubekezelelana kwegazi, ukushintsha kwemizwelo, ukuzuza kwesisindo nokukhula kwesidlo.

Kukhona nezinye izimpendulo ezimbi ezingenzeka ezihlobene nezinhlelo eziningi zomzimba womzimba. Ukwaziswa okugcwele okuphelele kukaRayos kuqukethe uhlu olubanzi. Ukusabela okungahambi kahle kwe-musculoskeletal ehlobene ne-corticosteroids kuhlanganisa i- osteonecrosis yamakhanda asezinsikazi nezinsizi, ukuphefumula kwamathambo , ukukhubazeka kwemisipha, ukulahlekelwa kwesisindo somzimba, ukuhlukunyezwa kwe-vertebral fractures, nokuhlukana kwamathambo.

Ukungafani

U-Rayos akufanele asetshenziswe iziguli ezine-hypersensitivity eyaziwa yi-prednisone noma ezinye izithako ezingasebenzi eziqukethwe kuthebhulethi.

Izixwayiso

Ukusebenzisana kwezidakamizwa

U-Rayos angase ahlanganyele no:

Qinisekisa ukuthi udokotela wakho uyazi yonke imithi kanye nezithako ozithatha manje. Kubalulekile ukuhlola ingozi engase ibe khona uma kuqhathaniswa nezinzuzo ezikhona zokwelashwa noRayos.

Uyini umehluko?

I-Rayos ihluke kanjani ku-prednisone ngokushesha? Ekuvivinyweni kwemitholampilo, uRayos wanikezwa ngo-10: 00 ngokudla. Isici sokukhishwa ukulibazisa sikaRayos savumela izinga lokuthathwa kwe-prednisone egazini lenzeke lapho amazinga e- cytokine eqala ukwanda phakathi nobusuku. Le ndlela yesenzo inganikeza ukulawula kangcono ukuvuvukala kwezinye iziguli.

Imithombo

Rayos. Ukubeka imininingwane.
http://www.rayosrx.com/PI/RAYOS-Ukubhala-Information.pdf

I-Horizon Pharma Yemezela Ukugunyazwa kwe-FDA ye-RAYOS® (prednisone) Amathebhulethi aDelayed Delayed-Release for Arthritis Ye-Rheumatoid kanye Nezinye Izinkomba Ezengeziwe. I-Horizon Pharma. Julayi 2012.
http://ir.horizon-pharma.com/releasedetail.cfm?ReleaseID=695983